Cardiorenal syndrome (CRS) in people with type 2 diabetes mellitus illustrates the bidirectional link between the heart and the kidneys, with acute or chronic dysfunction of one organ adversely impacting the function of the other. The cardiovascular and renoprotective benefits evidenced with sodium-glucose transporter-2 (SGLT-2) inhibitors make them a potential choice in the management of CRS.

Join the Worldwide CardioDiabetes on-demand symposium, “Practical Applications in Managing Patients with CardioRenal Disease: New SBLT-2 Study Data”, to learn more about the results of recent studies and how to apply this knowledge to your daily practice. It will be available during the upcoming 76th Annual Brazilian Congress of Cardiology and thereafter on this website. You can register via to view the program during the congress dates and check back here thereafter for open, on-demand access.

Click here to view the symposium faculty and agenda in full detail.

Worldwide CardioDiabetes held a virtual symposium during the recent 7th International Conference on Prehypertension, Hypertension, Metabolic Disorders and Cardiovascular Disease and it is now available on demand. “Diabetes and CardioRenal Disease: Can We Reduce the Impact of this Deadly Combination” features presentations by Drs. Andrew Boulton, George Bakris, Martin Rutter, and Philip Home, delving into the important topics of the kidney and cardiovascular risk, treating heart failure, and improving outcomes in diabetes beyond glucose control therapies.

Click here to view the program.